Layered double hydroxide–indomethacin hybrid: A promising biocompatible compound for the treatment of neuroinflammatory diseases

Indomethacin (INDO) demonstrates therapeutic efficacy in the treatment of neuroinflammatory diseases. Despite its importance as a drug, INDO causes gastrointestinal problems and adverse reactions central nervous system (CNS). In this study, we prepared nanoparticles layered double hydroxide (LDH) loaded with INDO. The structure nanohybrid (LDH-INDO) was synthesized via coprecipitation method, characterized using X-ray powder diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, thermogravimetric analysis–differential scanning colorimetry (TGA–DSC), field-emission electron microscopy (FE-SEM), ultraviolet (UV)–vis spectroscopy. Moreover, drug release profiles were investigated kinetic models. incorporated within LDH interlayer space 50% intercalation. anions from LDH-INDO after 10 h 90% at pH 4.8 ± 0.02 51% 7.4 0.02. results show that follow pseudo-second-order model. addition, lipopolysaccharide (LPS)-induced sickness behavior animals suggest recovery variables (weight food intake) used study. did not alter hepatic renal biomarkers. LPS increased number Iba1+ cells (microgliosis) caused morphological alterations these hippocampus somatosensory cortex. However, effect attenuated INDO, both free LDH-intercalated, regions brain.